Statistics for Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
Total visits
| views | |
|---|---|
| Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design | 16 |
Total visits per month
| views | |
|---|---|
| April 2024 | 0 |
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
File Visits
| views | |
|---|---|
| 13063_2022_Article_6897.pdf | 22 |
Top country views
| views | |
|---|---|
| United States | 5 |
| Vietnam | 4 |
| Ireland | 2 |
| Austria | 1 |
| Canada | 1 |
| Hong Kong SAR China | 1 |
Top city views
| views | |
|---|---|
| Hanoi | 4 |
| Dublin | 2 |
| Ashburn | 1 |
| Boardman | 1 |
| Edmonton | 1 |
| Philadelphia | 1 |
| Vienna | 1 |